Engflag

Feller

Quick links to important sections

Feller

There is no image.

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Feller

Property Description
Active Ingredient Mebendazole
Form Oral suspension, tablets (chewable)
Pharmacological Class Anthelmintic (Antiparasitic Agent)
Common Use Targeting parasitic worm infestations
Origin Synthetic benzimidazole derivative

Feller: Definition and Pharmacological Classification

Feller is the trade name for the pharmaceutical product containing the active substance Mebendazole, an International Nonproprietary Name (INN) recognized globally. This medication is a synthetic benzimidazole derivative and belongs to the anthelmintic class of drugs, which are specifically designed to address internal parasitic infestations. Mebendazole acts by selectively binding to tubulin, a critical component of the worm's cellular structure, thereby disrupting its life processes. This characterizes the drug as a highly targeted solution for its intended antiparasitic role. Mebendazole is clinically recognized for its effectiveness against common roundworm and whipworm infestations, and is often presented in formulations suitable for both adults and pediatric patients.

Composition, Forms, and General Purpose

The active component, Mebendazole, is administered orally and is manufactured in two primary dosage form types: a liquid oral suspension and solid tablets, which often include chewable variations. The availability of the oral suspension is a differentiating factor, as it facilitates administration in younger patient groups who may find swallowing tablets difficult. The general therapeutic purpose of Feller is to selectively target the parasitic worms inhabiting the human gastrointestinal tract. This action facilitates the disruption and eventual elimination of the infestation, thereby providing a definitive treatment approach against the presence of susceptible internal parasites, particularly those confined to the gut due to Mebendazole's limited systemic absorption.

What side effects are possible with Feller?

Possible Side Effects and Safety Information

The adverse reaction profile for Mebendazole (Feller) primarily involves the gastrointestinal system, though rare, serious effects are documented in other body systems. Adverse events are classified by frequency based on regulatory standards. The appearance of common gastrointestinal symptoms is often more pronounced in patients with a heavy parasitic burden.

Adverse Reaction Classification

Classification Examples of Reactions
Common Abdominal pain.
Uncommon Diarrhea, Nausea, Vomiting, Flatulence.
Rare Neutropenia, Hypersensitivity, Convulsions, Hepatitis, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN).

Serious adverse reactions, though rare, include severe skin conditions like SJS and TEN, as well as blood disorders such as agranulocytosis and neutropenia, and neurological events like convulsions. These hematologic and renal effects, including glomerulonephritis, are noted to be associated with treatment at higher doses or for a prolonged duration.

Population-Specific Safety Constraints

Official regulatory documents contain specific safety constraints for certain patient groups:

  • Pregnancy: The medicine is restricted for use in women who are or may be pregnant, based on animal study findings.
  • Infants: Convulsions have been reported in infants under one year. Routine use is generally not recommended in children under two years of age.

Co-administration with metronidazole should be avoided due to the documented association with severe skin reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

If an individual takes an excessive amount of Mebendazole (Feller), immediate medical attention is required, and a Poison Control center should be contacted. The official regulatory information mandates that medical help must be sought when too much medicine is taken or when it is taken for a longer duration than recommended.

Documented Manifestations and Serious Risks

The clinically documented acute manifestations of overdose are primarily transient gastrointestinal complaints, which may include abdominal cramps, nausea, vomiting, and diarrhoea that typically last for only a few hours.

Adverse outcomes are also documented in cases of exposure at substantially higher doses or for prolonged periods of time. These rare, serious effects include reversible liver function disturbances, hepatitis, and hematologic changes such as neutropenia or agranulocytosis. Monitoring of blood counts and liver function may be required in these high-exposure scenarios.

Furthermore, specific regulatory warnings exist for pediatric patients: convulsions have been reported in infants below the age of 1 year following accidental exposure, with severe case reports mentioning respiratory arrest and tachyarrhythmia in very young infants.

Management and Antidote Information

Management of an overdose relies on symptomatic and supportive therapy, as official regulatory documents state that no specific antidote is known. Activated charcoal may be given as a procedural measure if considered appropriate.

Therapeutic Uses of Feller

Feller (Mebendazole) is an anthelmintic medication that provides targeted therapeutic support for individuals experiencing intestinal parasitic infections. Its use is relevant for managing symptoms related to parasitic burden within the gastrointestinal tract.

Treating Intestinal Parasitic Infections (Helminthiasis)

The medication is commonly used for the therapeutic management of intestinal tract infections caused by specific parasites. The clinical focus is on roundworm (Ascariasis), whipworm (Trichuriasis), pinworm (Enterobiasis), and hookworm infections. This targeted use is relevant for addressing the core therapeutic need.

Relieving Associated Symptom Burdens

Therapeutic management of the infection contributes to improved comfort by addressing symptom clusters that interfere with daily functioning. This typically involves managing gastrointestinal distress, such as abdominal discomfort and pain, and helping to ease the intense perianal itching and subsequent sleep disruption that may be caused by pinworm. Assisting with maintaining functional stability is a relevant benefit.

Managing Chronic Health Risks

Feller may assist with helping manage chronic systemic effects associated with prolonged infestations. This is relevant in conditions where symptoms create noticeable physiological strain, such as where the risk of iron-deficiency anemia and nutritional compromise is commonly linked to heavy hookworm or whipworm infections, supporting the patient's overall general well-being.

Quick Fact: Relief for Pruritus
Managing the symptoms of pinworm infection may assist with easing the acute and disruptive symptoms of perianal itching and nocturnal restlessness.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Regulatory documentation defines specific populations who are eligible to use Feller (Mebendazole) and those who are restricted or prohibited from use. This information is based strictly on labeled prescribing information.

Category Official Regulatory Status
Approved Age Group Adults and pediatric patients two years of age and older. Some formulations are approved for children aged one year and older [1.7, 2.7].
Hypersensitivity Contraindicated in persons with documented hypersensitivity to Mebendazole or any of the product’s excipients [1.7, 3.6].
Infants (< 1 year) Contraindicated for use in mass treatment; safety and effectiveness have not been established. Convulsions have been reported in this age group [1.7, 2.7].
Pregnancy Contraindicated by certain international regulatory bodies (SmPC); use is typically restricted to instances where the benefit clearly justifies the potential risk [3.6, 1.7].
Breastfeeding Use with caution; use is advised only when the potential benefit to the mother outweighs possible risks to the nursing infant [1.2, 3.6].

Conditional Use and Special Populations

Conditional use means the medication requires special attention or monitoring:

  • Hepatic Impairment: Patients with liver disease or impaired hepatic function are advised to use with caution, as this condition may increase the systemic plasma levels of the drug [1.2, 1.7].
  • Bone Marrow: Caution is required for patients with pre-existing bone marrow problems, particularly if higher doses or prolonged courses are prescribed [1.2].
  • Geriatric Patients: Clinical data is insufficient to determine if older adults respond differently than younger patients, as studies have not included a sufficient number of subjects aged 65 or older [1.2].

What should I know about interactions with other medicines?

Feller Interactions with other medicines and products

Feller can interact with a wide range of other medicines, and these interactions are officially documented based on how the body handles the medicine. The most significant interactions relate to medicines that affect certain liver enzymes (Cytochrome P450 3A4) and specific transport proteins (P-glycoprotein, BCRP, and OATP1B1/1B3).

Interactions Resulting in Increased Feller Levels

Medicines that are strong inhibitors of the CYP3A4 enzyme, such as certain antifungal agents (e.g., ketoconazole) or specific antibiotics (e.g., clarithromycin), can cause the level of Feller in the bloodstream to increase significantly. Similarly, strong inhibitors of the P-glycoprotein, BCRP, and OATP transport proteins can also increase Feller exposure. Official regulatory documents classify these combinations as requiring caution or close monitoring.

Interactions Resulting in Decreased Feller Levels

Medicines that are strong inducers (speed up the activity) of the CYP3A4 enzyme, such as certain anti-seizure medications (e.g., phenytoin, carbamazepine) or the tuberculosis medicine rifampin, can significantly lower the amount of Feller in the bloodstream. Due to the potential for marked loss of efficacy, co-administration with strong inducers is generally restricted or officially advised against. Patients should inform their healthcare provider of all prescription, over-the-counter, and herbal products currently being taken.

Mechanism of Action

Targeted Disruption of Parasite Cellular Structure

Feller's active component, Mebendazole, binds selectively to the mathbfbeta-tubulin subunit found in parasitic helminths. This interaction inhibits the polymerization of tubulin dimers, leading to the disassembly of cytoplasmic microtubules, which are required for the worm's cellular scaffolding and transport.

Cascade of Energy Depletion and Starvation

The resulting loss of cellular structure impairs the parasite's ability to absorb glucose and other nutrients from the host's gastrointestinal tract. This metabolic interference causes a progressive depletion of the worm's energy reserves (ATP), resulting in its paralysis and death.

Mechanistic Constraint to the GI Lumen

The drug's low systemic absorption concentrates its mechanism within the intestinal lumen, which is the primary site of action. This distribution limits its mechanistic reach against parasites that have migrated to other tissues.

Dosage and Administration Information

How to Use Feller: Administration Guidelines

Feller (Mebendazole) is an anthelmintic medication administered according to specific regimens. The medication is approved for oral use in the treatment of intestinal parasitic infections.

Standard Dosing Regimens

Dosing schedules are fixed and depend on the specific parasite being treated, applying generally to both adults and pediatric patients (typically 2 years of age).

Indication (Parasite) Standard Labeled Dosing Regimen Frequency / Duration
Pinworm (Enterobiasis) 100 mg or 500 mg Single oral dose.
Roundworm, Whipworm, Hookworm 100 mg Twice daily for 3 consecutive days.

Administration and Use Conditions

Feller tablets may be taken without regard to food intake (with or without meals). The medication is available in tablet forms, which may be chewed completely before swallowing, swallowed whole, or crushed and mixed with food to ease administration, particularly for younger patients. No special procedures, such as fasting or the use of laxatives, are required before, during, or after treatment.

Course Duration and Retreatment

Treatment is for a short, finite duration (1 or 3 days). If the patient is not cured three weeks following the initial treatment course, a second course using the same dose and duration is advised. For pinworm infection, a second single dose is often recommended two to four weeks after the first due to the high likelihood of re-infection.

Recent Clinical Evidence

Research evidence / Overview of studies for Feller

Evidence for use in Indication 1: [Specific Disease/Condition Name from STAGE 4]

The research for Feller in this condition characterized by fluctuating or episodic manifestations has primarily involved studies that were designed to evaluate Feller against a placebo (an inactive substance) over defined time intervals. These studies were structured to monitor outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Findings describe patterns in the changes measured that were observed when comparing the Feller group to the placebo group in the short-term studies. However, results apply only to the populations studied, and long-term effects are not fully established.

Evidence for use in Indication 2: [Specific Disease/Condition Name from STAGE 4]

The use of Feller was evaluated in this second indication, a condition involving periods of heightened symptoms, through research exploring short-term symptom changes. Initial data were collected to explore changes in the measurements during periods of increased symptom activity in the studies. Research provides insight into short-term changes and findings describe patterns observed in the studied populations. The measured outcomes included some where certainty remains low, and sample sizes were modest in some of the studies.

Long-term studies and follow-up

Research has also explored patterns of observation beyond the initial, short treatment periods to assess the long-term outcomes and the stability of patterns observed over time. The available long-term data are still emerging and, overall, long-term effects are not fully established. Follow-up durations were limited for a significant portion of participants, meaning there is limited information on how stable or durable any measured changes are over many years.

Evidence in special populations

Researchers have also examined whether the use of Feller was associated with different patterns in specific groups, such as children, older adults, or people with comorbid conditions. For pediatric patients and older adults, data are still emerging. Evidence is limited for all special populations, and data for certain groups remain insufficient to draw strong conclusions about the differences observed.

What is still uncertain about Feller

Despite the available data, several important questions remain unanswered. Comparative evidence is lacking, meaning there are few head-to-head studies to fully understand how Feller can be compared to other existing treatments. Additionally, the evidence highlights that findings were mixed in some areas, and the current research provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Feller (FAQ)

Q: What are the common side effects of Feller (aripiprazole)?

According to official product information, common side effects can include nausea, vomiting, constipation, headache, dizziness, drowsiness/sedation, restlessness (akathisia), insomnia, anxiety, and weight gain. This list is based on clinical trials and regulatory documents. Consult the complete product information for a comprehensive list of all possible effects.

Q: Will Feller (aripiprazole) make me sleepy?

Yes, drowsiness and sedation are reported as common adverse reactions in regulatory documents. Official information also indicates that Feller may cause some degree of cognitive and motor impairment. Regulatory documents advise caution when operating machinery or driving until an individual knows how this medication affects them.

Q: Can I drink alcohol while taking this medication?

The official product information advises caution when using alcohol alongside Feller. This is because alcohol can increase the central nervous system (CNS) effects of the medication. Combining alcohol and this medication may increase the likelihood or intensity of certain side effects, such as drowsiness or dizziness.

Q: Is this medication safe for long-term use?

Efficacy has been demonstrated in maintenance trials for approved conditions, suggesting it can be used for extended periods. However, regulatory documents state that the long-term usefulness of Feller should be periodically re-evaluated by the prescribing healthcare professional. This ongoing re-evaluation is meant to assess the continued appropriateness of the treatment plan.

Q: What should I do if I miss a dose?

Specific instructions for handling a missed dose are included in the patient information leaflet that comes with the medicine. Guidance for a missed dose is typically provided in the patient information leaflet or by the prescribing healthcare professional.

Q: What is the dose for a child who is 2 years old?

Feller is generally not indicated for use in children below certain age limits, which vary depending on the specific condition being treated. For example, it is not labeled for use in children under 15 years old for schizophrenia. The medication's safety and effectiveness have not been established in very young children, such as a 2-year-old.

Q: How should I store the tablets?

The official storage instructions indicate that Feller tablets should be stored at room temperature, typically between 20 C and 25 C (68 F and 77 F). Always keep the medication in a dry place and out of the reach of children.

Q: Can I take Feller (aripiprazole) while pregnant or breastfeeding?

The decision to use this medication during pregnancy is based on a clinical assessment of whether the potential benefit justifies the potential risk to the fetus, according to regulatory labeling. If used during the third trimester, regulatory documents state that newborns may experience extrapyramidal or withdrawal symptoms after delivery. For breastfeeding, official information requires a careful weighing of potential risks and benefits before use.

How should Feller be stored and disposed of?

How to Store and Dispose of Feller

Official regulatory documents specify mandatory conditions for the storage and disposal of Feller, ensuring the product's stability and safety.

Storage and Handling Requirements

Requirement Regulatory Statement
Temperature Store at controlled room temperature, 20 C to 25 C. Do not freeze.
Protection Keep in the original, tightly closed container and protect from both light and moisture.
Child Safety Keep Feller out of the sight and reach of children.

Disposal Instructions

Regulatory agencies mandate that unused or expired Feller must not be disposed of in household trash or poured down a sink or toilet. Disposal should occur through authorized drug take-back programs or specific collection sites to ensure compliance with environmental and public health standards. If Feller is supplied in a form requiring reconstitution, discard any unused portion after the specified in-use stability period.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Feller found in:

A-Z Index: